Mesothelioma Prognosis

Fact Checked

A mesothelioma prognosis is what doctors describe as an overall outlook for a specific patient. Mesothelioma is an aggressive cancer with an average life expectancy of 14 to 22 months, but it is often terminal with most patients living only 1 year after diagnosis. A patient’s prognosis helps determine the treatment options they can pursue.

Free 2019 Mesothelioma Guide
Learn about the factors that influence a mesothelioma prognosis from leading expert Dr. David Sugarbaker.
Learn about the factors that influence a mesothelioma prognosis from leading expert Dr. David Sugarbaker.

What Is the Prognosis for Mesothelioma?

The prognosis for most mesothelioma patients is generally poor because there is no cure for this disease.

Prognosis is often measured in terms such as “good,” “favorable,” “bad” or “poor” based on how the cancer is expected to progress. It includes the prospect of recovery and helps determine what treatment options may be available.

When patients ask about their prognosis, what they usually want to know is how long they will live.

How Long Do You Live After Being Diagnosed with Mesothelioma?

Most patients live about one year after being diagnosed with mesothelioma.

How long you live with mesothelioma depends on the stage you are diagnosed at and how well you respond to mesothelioma treatments.

Early-Stage Prognosis

People diagnosed early, in stage 1 or stage 2, often qualify for surgery, which offers the best chance at long-term survival. Approximately 20 percent of pleural mesothelioma patients are diagnosed early enough to qualify for surgery. Stage 1 patients who undergo surgery have a median life expectancy of 22.2 months.

Late-Stage Prognosis

Most patients are diagnosed late, at stage 3 or 4, and do not qualify for surgery. Stage 4 patients who undergo treatment have a median life expectancy of 14.9 months.

Although statistics play a part in determining your prognosis, every mesothelioma case is unique.

Some mesothelioma patients are beating the typical outlook thanks to advances in treatment and care. Survivors credit life span increases to multimodal treatment, improvements in their diet and complementary therapies.

Improving a Mesothelioma Prognosis

Average mesothelioma prognosis with treatment
Average life expectancy of mesothelioma patients who undergo treatment.

You can choose to be proactive and take steps to improve your prognosis. You can’t change important prognostic factors such as your age, mesothelioma type or cancer stage. But, you can improve your overall health and elect anti-cancer treatment such as chemotherapy.

In addition to undergoing treatments that control the cancer, you should follow a healthy nutrition plan with a well-balanced diet. Good nutrition can also ease treatment side effects and cancer symptoms.

Mesothelioma Nutrition Guide

Free Mesothelioma Nutrition Guide

Eating right and balancing your diet while undergoing mesothelioma treatment can help ease your symptoms.

Get Free Recipes & Tips

Eating right and balancing your diet while undergoing mesothelioma treatment can help ease your symptoms.

Treatment Options for Mesothelioma

The most effective treatments for mesothelioma include surgery and chemotherapy. Radiation therapy and immunotherapy play a role in multimodal therapy and clinical trials.

Most patients are diagnosed too late to qualify for surgery and only undergo chemotherapy. Chemotherapy, radiation therapy and immunotherapy are available for patients at all stages.

Cancer therapies are expensive, but many patients are eligible for financial compensation to cover the costs of mesothelioma treatment. Veterans may qualify for free or low-cost treatment at a VA hospital.

A specialized mesothelioma lawyer can advise patients on other possible sources of compensation.

Did You Know?

The average cost of mesothelioma treatment is $11,000 to $12,000 a month.
An experienced mesothelioma lawyer can help you and your family get money to cover treatment costs, travel expenses and more.

Learn how to choose a mesothelioma lawyer

Mesothelioma Prognosis After Chemotherapy

The chemotherapy response rate is nearly 50 percent. This means about half of mesothelioma patients experience tumor shrinkage or no new tumor growth for a period of time.

A 2016 study published in the journal Clinical Epidemiology found that patients receiving chemotherapy lived an average of 12 months, while those who elected no treatment lived an average of four months.

Mesothelioma Prognosis After Surgery

People diagnosed in stage 1, 2 or 3 may qualify for aggressive surgery. Tumor-removing surgery offers the greatest opportunity for long-term survival. Surgery can involve removal of an entire lung, part of the lung or only the removal of the lining of the lung, known as the pleura.

Many people wonder if a person can live with one lung, and the answer is yes. Surgery is regularly combined with chemotherapy and sometimes radiation therapy or immunotherapy. It can improve survival by years in some patients.

Leading expert for mesothelioma treatment Dr. David Sugarbaker provides insights on things patients should do before surgery.

Mesothelioma Prognosis After Radiation Therapy

Radiation therapy on its own is used to shrink painful tumors growing into the chest wall. This application does not directly impact prognosis.

When combined with other therapies, such as surgery, radiation therapy can help delay or prevent local cancer recurrence.

Experimental Therapies

Experimental therapies, such as immunotherapy and photodynamic therapy, are available through clinical trials and compassionate use programs.

Peritoneal Mesothelioma Treatment

Patients with peritoneal mesothelioma can improve their prognosis with a combination of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

It involves adding chemotherapy drugs to a heated saline solution and pumping it directly into the patient’s abdomen. Research shows roughly half of patients who underwent this procedure survived more than five years.

Common Mesothelioma Treatment Options

Prognosis by Mesothelioma Type

Pleural Mesothelioma Prognosis

The prognosis for patients with pleural mesothelioma — the most common type — is not favorable. Research shows approximately 40 percent of patients survive at least one year after diagnosis.

Some patients who undergo multimodal treatment and complementary therapies survive several years after diagnosis. About 9 percent of pleural mesothelioma patients survive more than five years.

Gene Hartline diagnosed with pleural mesothelioma in 2016

“I would tell anyone who gets diagnosed with this disease, don’t just take the first advice you get and give up. Look around and see what is out there.”

Peritoneal Mesothelioma Prognosis

Patients with peritoneal mesothelioma have a far better prognosis. New treatments for abdominal cancer, such as heated chemotherapy, have improved the chance of long-term survival.

Around 50 percent of patients who undergo surgery with heated chemotherapy live longer than five years.

Pericardial Mesothelioma Prognosis

Prognosis for pericardial mesothelioma is generally poor. Around half of patients survive six months. Rare cases of five-year survival have been reported and usually involve treatment including surgery and chemotherapy.

Testicular Mesothelioma Prognosis

Although testicular mesothelioma is the rarest type, its prognosis is typically the best. Average survival is around two years and some patients live more than a decade.

Prognosis by Mesothelioma Stage

Mesothelioma Prognosis at Stage 1

Patients diagnosed at stage 1 have the best prognosis. Aggressive treatments are recommended to people in otherwise good health.

Survival Rates for Stage 1A and Stage 1B

  • Stage 1A: The two-year survival rate is 46 percent and the five-year survival rate is 16 percent.
  • Stage 1B: The two-year survival rate is 41 percent and the five-year rate survival is 13 percent.
  • Median overall survival at stage 1 is 22.2 months with surgery.

Learn More About Stage 1 Mesothelioma

Mesothelioma Prognosis at Stage 2

Patients diagnosed at stage 2 have a better prognosis than late-stage patients. Aggressive treatment plans are also recommended at this stage.

  • The two-year survival rate for pleural mesothelioma is 38 percent and the five-year survival rate is 10 percent.
  • Median overall survival at stage 2 is 20 months with surgery.

Learn More About Stage 2 Mesothelioma

Mesothelioma Prognosis at Stage 3

Prognosis becomes more unfavorable for patients diagnosed in stage 3. Some stage 3 patients qualify for aggressive treatment plans.

Survival Rates for Stage 3A and Stage 3B

  • Stage 3A: The two-year survival rate is 30 percent and the five-year survival rate is 8 percent.
  • Stage 3B: The two-year survival rate is 26 percent and the five-year survival rate is 5 percent.
  • Median overall survival at stage 3 is 17.9 months with surgery.

Learn More About Stage 3 Mesothelioma

Mesothelioma Prognosis at Stage 4

The prognosis at stage 4 is generally poor. Palliative treatments are recommended at this stage to control symptoms and extend survival as long as possible.

  • The two-year survival rate for pleural mesothelioma is 17 percent and the five-year survival rate is less than 1 percent.
  • Median overall survival at stage 4 is 14.9 months with treatment.

Learn More About Stage 4 Mesothelioma

Mesothelioma Nutrition Guide

Find a Mesothelioma Specialist

Help improve your prognosis by getting treatment from a doctor who specializes in mesothelioma.

Get Help Now

Other Factors Affecting Mesothelioma Prognosis

Cell Type

The types of cells that make up the tumor can impact your prognosis.

  • Epithelioid cells: Patients with this cell type tend to live longer than those with other cell types. People with epithelioid tumors live an average of 200 days longer.
  • Sarcomatoid cells: These cells are associated with the poorest prognosis because they are considered more aggressive and harder to treat.
  • Biphasic cells: The prognosis for this type depends on the ratio of sarcomatoid to epithelial cells. The more epithelial cells, the better the prognosis.

Age

Younger people have a better prognosis with mesothelioma than older people. More than half of patients diagnosed under age 50 live at least a year with mesothelioma. Under a third of patients diagnosed over age 75 live that long.

Gender

Gender has a significant impact on mesothelioma prognosis. Women with mesothelioma live longer than men do.

Researchers do not fully understand why women live longer. They suspect that hormones may play a role. They do know that women are more often diagnosed with peritoneal mesothelioma. Peritoneal carries a better prognosis than pleural mesothelioma.

Race

Race plays a role in mesothelioma prognosis. In 2013, the five-year survival rate was 8.7 percent for white people and 10 percent for black people.

Black women tend to live the longest with mesothelioma. In 2013, the five-year survival rate was 13.6 percent for white women and 30.1 percent for black women.

Mesothelioma Remission and Recurrence

A cancer’s prognosis includes the chances of recovery, which is called remission. It involves a measurable tumor size decrease, which can be described as partial or complete.

  • Remission is partial when the cancer shrinks in size. Partial remission usually involves at least a 50 percent reduction in tumor size.
  • Remission is complete when the cancer disappears entirely.

Complete remission is rare with mesothelioma. Partial remission is more common. Patients can live for years in partial remission.

Unfortunately, mesothelioma tends to recur whether partial or complete remission is achieved. When mesothelioma recurs, it usually recurs locally or regionally rather than distantly.

Clinical Trials

Many clinical trials look for patients with a mesothelioma recurrence to test new and innovative therapies. They test second-line therapies to control the cancer when it recurs.

The goal of these trials is to find more ways to keep mesothelioma in control once it returns. Researchers need a wide range of participants. Patients with prior treatment who are now living with an advanced disease are ideal candidates for clinical trials.

Doctor conducting medical testing using lab equipment

Find Clinical Trials for Mesothelioma Patients

Get help improving your prognosis by finding and enrolling in a mesothelioma clinical trial today.

Find A Clinical Trial

Understanding Prognostic Terms

Life Expectancy

The term “life expectancy” refers to the average age a person or population is expected to live based upon their location and other demographics. Mesothelioma can shorten a person’s life expectancy by several years or decades. It all depends on their age at diagnosis and how long they live with mesothelioma.

For example, a healthy 70-year-old man has a life expectancy of 14 years. If he is diagnosed with stage 4 mesothelioma, his life expectancy is reduced to two years.

Read More About Mesothelioma Life Expectancy

Survival Rates

Survival rates measure how long most people live with mesothelioma. Your prognosis is primarily based on the cancer’s average survival rates.

The National Cancer Institute says the five-year survival rate for mesothelioma was 9 percent between 2007 and 2013.

Mesothelioma Survival Rate Factors

Death Rates

A cancer’s death rate, also called mortality rate, describes how many people die from the cancer. It plays a role when doctors estimate a patient’s prognosis.

Mesothelioma mortality rates are often defined in relation to patient age, gender, race and state of residence.

Survivors Who Surpassed Their Prognosis

Although recurrence is common, people diagnosed with mesothelioma are overcoming their initial prognoses.

Whether it’s because of their particular type of mesothelioma, specialized treatments, genetics or simply changing how they live their lives through improved nutrition and exercise, it’s important to keep hope alive.

Some survivors live years or even a decade or more past their initial prognosis.

Chris Gibney, pleural mesothelioma survivor

Chris Gibney

Pleural mesothelioma survivor

Diagnosed in 2005, Chris Gibney far surpassed his pleural mesothelioma diagnosis. In March 2017, he and his wife welcomed a group of exchange students from Germany to their home. Gibney credits his excellent medical team and a family support group for surviving more than a decade past his prognosis.

Beth Mixon, peritoneal mesothelioma survivor

Beth Mixon

Peritoneal mesothelioma survivor

At the time of Beth Mixon’s peritoneal mesothelioma diagnosis in 2000, the majority of patients lived less than two years after treatment. Despite a grim prognosis, Mixon is still going strong 17 years after an aggressive cytoredutive surgery.

Kasie Coleman, peritoneal mesothelioma survivor

Kasie Coleman

Peritoneal mesothelioma survivor

Diagnosed with peritoneal mesothelioma in 2010, Kasie Coleman underwent several cycles of chemotherapy and HIPEC treatments. Her cancer went into remission in 2012.

Read More Survivor Stories

Join Our Next Mesothelioma Support Group

Register Now
Asbestos.com Mesothelioma Packet

Free Guide to Help Improve Prognosis

Claim Yours

Get Help Covering Expenses

Find out How

Registered Nurse and Patient Advocate

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Reviewed by placeholder
Medical Review By

11 Cited Article Sources

  1. National Cancer Institute. (2019, March 7). Malignant mesothelioma Treatment (PDQ).
    Retrieved from: https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq
  2. American Cancer Society. (2019, January 9). What are the key statistics of malignant mesothelioma?
    Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/about/key-statistics.html
  3. Shavelle, R. et al. (2017). Life Expectancy in Pleural and Peritoneal Mesothelioma.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292397/
  4. CDC. (2017, March 3). Malignant Mesothelioma Mortality – United States, 1999-2015.
    Retrieved from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6608a3.htm
  5. Beebe-Dimmer, J.L. et al. (2016). Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087771/
  6. Nowak, A.K. et al. (2016). The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/27687963
  7. Leuzzi, G. et al. (2015). Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: A multicenter analysis.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/26163973
  8. National Cancer Institute. (2013). SEER Cancer Statistics Reviews 1975-2010: Mesothelioma.
    Retrieved from: http://seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_17_mesothelioma.pdf
  9. Lindenmann, J. et al. (2013). Multimodal therapy of malignant pleural mesothelioma: Is the replacement of radical surgery imminent?
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/23171517
  10. Sugarbaker, D.J. et al. (2011). Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/21310625
  11. SEER. (n.d.). SEER Cancer Statistics Review 1975-2014. Retrieved from: https://seer.cancer.gov/csr/1975_2014/results_merged/topic_survival.pdf
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified September 27, 2019

Chat live with a patient advocate now